1731 related articles for article (PubMed ID: 28536906)
21. Targeting of B-cell receptor signalling in B-cell malignancies.
Jerkeman M; Hallek M; Dreyling M; Thieblemont C; Kimby E; Staudt L
J Intern Med; 2017 Nov; 282(5):415-428. PubMed ID: 28295729
[TBL] [Abstract][Full Text] [Related]
22. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
23. Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition.
Dias AL; Jain D
Cardiovasc Hematol Agents Med Chem; 2013 Dec; 11(4):265-71. PubMed ID: 24433470
[TBL] [Abstract][Full Text] [Related]
24. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
25. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.
Burger JA
Curr Hematol Malig Rep; 2014 Mar; 9(1):44-9. PubMed ID: 24357428
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Marostica E; Sukbuntherng J; Loury D; de Jong J; de Trixhe XW; Vermeulen A; De Nicolao G; O'Brien S; Byrd JC; Advani R; McGreivy J; Poggesi I
Cancer Chemother Pharmacol; 2015 Jan; 75(1):111-21. PubMed ID: 25381051
[TBL] [Abstract][Full Text] [Related]
27. Ibrutinib treatment of CLL: the cancer fights back.
Young RM; Staudt LM
Cancer Cell; 2014 Jul; 26(1):11-3. PubMed ID: 25026208
[TBL] [Abstract][Full Text] [Related]
28. Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
Wang X; Fei Y; Liu X; Zhang T; Li W; Jia X; Liu X; Qiu L; Qian Z; Zhou S; Ren X; Zhai Q; Meng B; Li L; Zhang H
Aging (Albany NY); 2021 Sep; 13(17):21102-21121. PubMed ID: 34508613
[TBL] [Abstract][Full Text] [Related]
29. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Wang ML; Rule S; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE; Williams ME; Barrientos JC; Chmielowska E; Radford J; Stilgenbauer S; Dreyling M; Jedrzejczak WW; Johnson P; Spurgeon SE; Li L; Zhang L; Newberry K; Ou Z; Cheng N; Fang B; McGreivy J; Clow F; Buggy JJ; Chang BY; Beaupre DM; Kunkel LA; Blum KA
N Engl J Med; 2013 Aug; 369(6):507-16. PubMed ID: 23782157
[TBL] [Abstract][Full Text] [Related]
30. The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.
Bhatt V; Alejandro L; Michael A; Ganetsky A
Pharmacotherapy; 2014 Mar; 34(3):303-14. PubMed ID: 24338680
[TBL] [Abstract][Full Text] [Related]
31. Ibrutinib in CLL/SLL: From bench to bedside (Review).
Zi F; Yu L; Shi Q; Tang A; Cheng J
Oncol Rep; 2019 Dec; 42(6):2213-2227. PubMed ID: 31638169
[TBL] [Abstract][Full Text] [Related]
32. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
[TBL] [Abstract][Full Text] [Related]
33. Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials.
Brown JR
Curr Hematol Malig Rep; 2013 Mar; 8(1):1-6. PubMed ID: 23296407
[TBL] [Abstract][Full Text] [Related]
34. Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.
Alinari L; Quinion C; Blum KA
Clin Pharmacol Ther; 2015 May; 97(5):469-77. PubMed ID: 25670208
[TBL] [Abstract][Full Text] [Related]
35. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
36. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Advani RH; Buggy JJ; Sharman JP; Smith SM; Boyd TE; Grant B; Kolibaba KS; Furman RR; Rodriguez S; Chang BY; Sukbuntherng J; Izumi R; Hamdy A; Hedrick E; Fowler NH
J Clin Oncol; 2013 Jan; 31(1):88-94. PubMed ID: 23045577
[TBL] [Abstract][Full Text] [Related]
37. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
Geethakumari PR; Awan F
Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
[TBL] [Abstract][Full Text] [Related]
38. PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.
Winer ES; Ingham RR; Castillo JJ
Expert Opin Investig Drugs; 2012 Mar; 21(3):355-61. PubMed ID: 22300471
[TBL] [Abstract][Full Text] [Related]
39. Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
Kaur V; Swami A
Ann Hematol; 2017 Jul; 96(7):1175-1184. PubMed ID: 28342031
[TBL] [Abstract][Full Text] [Related]
40. Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia.
Muhowski EM; Ravikrishnan J; Gordon B; Yu L; Misra S; Walker B; Eathiraj S; Sampath D; Rogers KA; Byrd JC; Woyach JA
J Hematol Oncol; 2022 Nov; 15(1):166. PubMed ID: 36380319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]